Genomics England, with the consent of participants and the support of the public, is creating a lasting legacy for patients, the NHS and the UK economy, through the sequencing of 100,000 genomes by 2019. It has four main aims:
to bring benefit to patients
to create an ethical and transparent programme based on consent
to enable new scientific discovery and medical insights
to kickstart the development of a UK genomics industry
The project is focusing on patients with a rare disease and their families, as well as patients with certain common cancers (breast, bowel, ovarian, prostate, or lung). We will also be recruiting patients with chronic lymphocytic leukemia (CLL) in collaboration with existing clinical trials.